← All indications
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
Drugs by status
Approved for this indication (7)
Phase 4 trials (7)
Phase 3 trials (87)
- Prolgolimab
- paclitaxel
- hs-20093
- iparomlimab
- meclinertant
- ssgj-707
- methylcobalamin
- pemetrexed
- lapatinib
- pembrolizumab
- ql1604
- adagrasib
- doxorubicin
- olaparib
- fludeoxyglucose f-18
- zg006
- zkab001
- oxaliplatin
- darbepoetin alfa
- Chiauranib
- aflibercept
- tiragolumab
- enoxaparin
- amrubicin
- capecitabine
- cyclophosphamide
- famitinib
- hlx10
- urea
- zimberelimab
- +57 more
Phase 2 trials (292)
- htmc0435
- crizotinib
- tinostamustine
- prexasertib
- gimatecan
- ba3071
- mycophenolate
- js201
- cc-90011
- fluorouracil
- vinorelbine
- tedopi
- oblimersen sodium
- human fecal microbiota
- dasatinib
- mk-5890
- cemiplimab
- skb264
- dec-205/ny-eso-1 fusion protein cdx-1401
- roniciclib
- sm08502
- biw-8962
- veliparib
- necitumumab
- kpt-330
- blex 404
- nogapendekin alfa inbakicept
- lamivudine
- thymalfasin
- trastuzumab emtansine
- +262 more
Phase 1 trials (133)
- ly4175408
- [203pb]vmt-α-net
- rp12146
- lb2102
- entinostat
- incagn02390
- azd8701
- ct-0508
- gen-011
- imu-201
- Senaparib
- bortezomib
- buparlisib
- [68ga]ga dota-5g
- xmab22841
- gallium-68-dotatate
- decitabine
- slv-154
- personalized synthetic long peptide vaccine
- mgc026
- tsr-022
- sgn-ceacam5c
- abbv-181
- ab248
- nms-03305293
- amg 119
- porfimer
- panobinostat
- syha1807
- asn007
- +103 more
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (90)
- AbbVie
- Poniard Pharmaceuticals
- SmithKline Beecham
- Celgene
- Cephalon
- Amgen
- United Therapeutics
- Roche
- Imclone
- AstraZeneca
- Merck
- Eli Lilly
- Merck KGaA
- Aventis
- Pfizer
- Sanofi
- Ipsen
- BeOne Medicines
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ShangHai HaiHe Pharmaceutical
- Shanghai Henlius Biotech
- Zai Lab Pty. Ltd.
- Chong Kun Dang Pharmaceutical
- EpicentRx, Inc.
- PharmaMar
- Shanghai Junshi Bioscience Co.,Ltd.
- Ziopharm
- Medical Research Council
- +60 more
Organization Involved with Phase 2 Indications (254)
- Zenith Epigenetics
- Seattle Genetics
- AnewPharma
- Millennium Pharmaceuticals
- Vertex
- Advanced Accelerator Applications
- Clovis Oncology
- OSI Pharmaceuticals
- Advaxis, Inc.
- Advenchen Laboratories, LLC
- Astellas
- Immunomedics
- Schering-Plough
- Aeglea Biotherapeutics
- Merck Serono
- Genentech
- Pharmacia & Upjohn
- Plexxikon
- Aileron Therapeutics
- Genzyme
- Sanofi-Synthelabo
- Ariad Pharmaceuticals
- Ascenta Therapeutics
- Ascentage Pharma Group Inc.
- AurKa Pharma Inc.
- Bayer
- Cancer Insight, LLC
- G1 Therapeutics, Inc.
- Hikma
- Innovent Biologics (Suzhou) Co. Ltd.
- +224 more
Organization Involved with Phase 1 Indications (56)
- Incyte
- Pinnacle Biologics
- Spectrum Pharmaceuticals
- Medivation
- Exelixis
- MedImmune
- Wyeth
- Fate Therapeutics
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Chipscreen Biosciences, Ltd.
- Genocea Biosciences, Inc.
- Central European Society for Anticancer Drug Research (CESAR)
- Oncology Institute of Southern Switzerland
- Augusta University
- Baylor University
- Cancer Trials Ireland
- HealthPartners Institute
- Rocky Mountain Cancer Centers
- Shiga University
- Sichuan University
- Universidad Complutense de Madrid
- Thomas Jefferson University
- University of Nebraska
- University of Southern California
- Virginia Commonwealth University
- University of Virginia
- Columbia University
- Comprehensive Cancer Centers of Nevada
- Xencor
- +26 more
Organization Involved with Other Experimental Indications (6)